Pulmonary Hypertension in Pregnancy


15


 


Pulmonary Hypertension in Pregnancy


 


Nisha Garg and Stephanie Martin



Key Points


Pulmonary hypertension is defined as an elevated mean pulmonary arterial pressure >25 mmHg at rest confirmed by right heart catheterization


Pulmonary hypertension in pregnancy should be managed closely by a pulmonary hypertension specialist as part of a multidisciplinary team approach at an appropriate level of maternal care


Pregnancy is contraindicated in all patients with pulmonary hypertension


Epoprostenol is the most commonly used drug for pulmonary hypertension in pregnancy


Both BNP and pro-BNP levels have been shown to correlate with survival in patients with pulmonary hypertension


 


Introduction


Pulmonary hypertension is one of the highest risk medical conditions encountered in pregnancy. This rare, progressive condition has a prevalence of 9.7 cases per 100,000 that preferentially affects young women of child-bearing age [1] with a female to male ratio of almost 2:1 [2,3]. The physiologic burden of pregnancy in pulmonary hypertension is an area of great concern and is associated with high rates of maternal and fetal morbidity and mortality. Given the complexity of pulmonary hypertension in pregnancy, it is important to manage it with a multidisciplinary approach.


 


Definition


Pulmonary hypertension is defined as an elevated mean pulmonary arterial pressure (mPAP) 25 mmHg at rest confirmed by right heart catheterization, and is considered severe when mPAP is 50 mmHg [4].


Pulmonary hypertension encompasses a group of diseases with various pathophysiologies, including pulmonary arterial hypertension (PAH), pulmonary hypertension related to left heart disease, pulmonary hypertension related to lung disease, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension with unclear and/or multifactorial mechanisms. PAH is characterized by precapillary pulmonary hypertension, that is, pulmonary artery wedge pressure of <15 mmHg and pulmonary vascular resistance of >3 Wood units in the absence of underlying lung parenchymal or thromboembolic/vascular disease [4]. The World Health Organization (WHO) has classified pulmonary hypertension into five groups based upon etiology (Table 15.1).































Table 15.1


World Health Organization Classifications of Pulmonary Hypertension




Etiologies


Group 1


Pulmonary arterial hypertension


Idiopathic


Hereditary


Drug/toxin-induced


Associated with:


Connective tissue diseases


HIV infection


Portal hypertension


Congenital heart disease


Schistosomiasis


Group 2


Pulmonary hypertension due to left heart disease


Left ventricular systolic dysfunction


Left ventricular diastolic dysfunction


Valvular disease


Cardiomyopathies


Left heart inflow/outflow tract obstruction


Pulmonary vein stenosis


Group 3


Pulmonary hypertension due to lung disease and/or hypoxia


Chronic obstructive pulmonary disease


Interstitial lung disease


Restrictive/obstructive lung disease


Sleep-disordered breathing


Group 4


Chronic thromboembolic pulmonary hypertension


Chronic thromboembolic pulmonary hypertension


Other pulmonary artery obstructions


Group 5


Pulmonary hypertension with unclear multifactorial mechanisms


Hematologic disorders


Hemolytic anemia


Myeloproliferative disorders


Splenectomy


Systemic disorders


Sarcoidosis


Pulmonary histiocytosis


Lymphangioleiomyomatosis


Neurofibromatosis


Metabolic disorders


Thyroid disorders


Glycogen storage disease


Fibrosing mediastinitis


Chronic renal failure with or without dialysis


Genetic Factors


Familial or inherited PAH constitutes less than 10% of cases. Mutations in two genes in the transforming growth factor beta-receptor pathway, BMPR2 and activin-like kinase 1, have been linked to this condition, with the majority (50%–90%) attributed to BMPR2 mutations. Familial PAH is characterized by incomplete penetrance, however when expressed it is associated with earlier onset and more severe disease.


Drugs


Drug-induced PAH is associated with certain appetite suppressants that increase serotonin release, such as fenfluramine and dexfenfluramine. Pulmonary hypertension is also associated with use of illicit drugs such as cocaine and methamphetamine.


Connective Tissue Diseases


Certain connective tissue diseases are associated with a primary pulmonary arteriopathy. This most commonly occurs in patients with CREST syndrome, or the limited cutaneous form of systemic sclerosis. At autopsy, up to 80% of patients have histologic evidence of pulmonary arterial hyperplasia, however less than 10% actually develop clinical disease.


Autoimmune Disorders


Pulmonary hypertension has also been associated with other autoimmune disorders such as systemic lupus erythematosus, mixed connective tissue disease, and rheumatoid arthritis.


Infections


In patients with HIV, studies have suggested an incidence of pulmonary hypertension of 0.5%, which is significantly higher than the general population. In these cases, the development of pulmonary hypertension appears to be independent of CD4 count or opportunistic infections, and is directly proportional to the duration of HIV infection. The mechanism of action of PAH in HIV patients is unclear, and routine screening is not recommended.


Portal Hypertension


Pulmonary artery hypertension also appears to be associated with portal hypertension with an estimated prevalence of 2%–6%, and the risk of developing disease increases with the duration of portal hypertension.


Pulmonary Arterial Hypertension


Finally, PAH is a well-recognized complication of uncorrected congenital heart disease involving increased pulmonary blood flow and systemic to pulmonary shunts. Common examples include unrepaired ventricular or atrial septal defects, and patent ductus arteriosus. These conditions may progress into Eisenmenger syndrome, that is, the reversal of left-to-right shunt flow due to elevation of pulmonary artery pressures above that of systemic pressures. Pulmonary hypertension is a known complication of sickle cell disease, with an estimated prevalence of 10%–30%. The etiology of pulmonary hypertension in these patients is felt to be pulmonary vasculopathy, but also may be secondary to thromboembolic events, restrictive lung disease, and/or left heart disease [5].


 


Diagnosis


The diagnosis of pulmonary hypertension is established based on clinical presentation, physical examination, and the results of diagnostic testing summarized in Table 15.2.















Table 15.2


Diagnosis of Pulmonary Hypertension


History


Physical Examination


Diagnostic Tests


Fatigue


Weakness


Shortness of breath


Dry cough


Hemoptysis


Exercise-induced nausea/vomiting


Hoarseness


Wheezing


Chest pain


Syncope


Abdominal distention


Ankle edema


Loud pulmonary component of second heart sound (P2)


Third heart sound (S3)


Left parasternal lift


Systolic murmur of tricuspid regurgitation


Diastolic murmur of pulmonary regurgitation


Elevated jugular venous pressure


Hepatomegaly


Ascites


Peripheral edema


EKG


Tall P waves—P pulmonale, right axis deviation, right ventricular hypertrophy, prolonged QTc, atrial arrhythmias—flutter/fibrillation in 25% patients with longstanding disease [6]


CXR


Central pulmonary arterial dilation with peripheral “pruning” of vessels


Pulmonary function test


Reduced lung volume


Decreased lung diffusion capacity


Peripheral airway obstruction


Sleep study


Nocturnal hypoxemia and central sleep apnea 70%–80% [7]


Arterial blood gas


Hypoxemia with normal/decreased arterial carbon dioxide pressure


Echocardiography


Elevated pulmonary artery systolic pressure


Dilated right ventricle


Flattening of the interventricular septum


Ventilation/perfusion lung scan


High resolution computed tomography and pulmonary angiography


Cardiac magnetic resonance imaging


Laboratory


Hepatitis serology


HIV


ANA, dsDNA, anti-Ro, U3 RNP, U1 RNP


Antiphospholipid antibodies


NT pro-BNP


Abdominal ultrasound


Right heart catheterization with vasoreactivity testing


Minute walk test


Cardiopulmonary exercise testing


Symptoms


Clinical manifestations of pulmonary hypertension can be nonspecific and include exertional dyspnea and fatigue. The condition is progressive, and therefore symptoms typically worsen over time. As the disease progresses, increasing pulmonary pressures lead to right heart failure and symptoms become more pronounced. These include chest pain, syncope, peripheral edema, and right upper quadrant pain due to hepatic congestion. Because of the nonspecific nature of early symptoms, delays are common, and the diagnosis of pulmonary hypertension may not even be established prior to pregnancy. In fact, 24% of pulmonary hypertension due to congenital heart disease is diagnosed during pregnancy, often presenting in the second or third trimester with shortness of breath [8,9].


Physical Examination


Findings of pulmonary hypertension include increased P2, prominent a-wave in the jugular venous pulse, right-sided S4, and right-sided murmurs.


Diagnostic Testing


Further evaluation includes EKG and B-type natriuretic peptide (BNP) level. If these are normal, then pulmonary hypertension is unlikely [10]. Both BNP and pro-BNP levels have been shown to correlate with survival, and possibly with right ventricular enlargement and dysfunction [5].


If pulmonary hypertension is suspected, an echocardiogram is indicated. Echocardiography can estimate pulmonary artery pressures. Additional findings on echocardiogram related to severe pulmonary hypertension include right ventricular enlargement and tricuspid regurgitation. However, it is important to recognize that echocardiography is a screening tool and does not definitively diagnose pulmonary hypertension. It may especially have a higher false positive rate in detecting pulmonary hypertension in pregnant patients [11,12]. This may be related to the increased blood volume and decrease in systemic vascular resistance that are associated with pregnancy. This may lead to an increase in size of the inferior vena cava, thus exaggerating the estimated right atrial pressure and pulmonary artery systolic pressure. Right heart catheterization is required for definitive diagnosis of pulmonary hypertension and to accurately determine the severity. However, cardiac catheterization is an invasive procedure that carries a 1%–5% risk of complications including pneumothorax, bleeding, and infection [11]. Therefore, the indications for right heart catheterization are based on initial echocardiographic findings. If echocardiogram shows findings suggestive of pulmonary hypertension (elevated peak tricuspid regurgitation velocity, flattening of the interventricular septum, increased pulmonary artery diameter, etc.), then further investigation of pulmonary hypertension with right heart catheterization is indicated [3,10].


 


Pregnancy Risks and Antepartum Care


Pulmonary hypertension in pregnancy carries a high maternal mortality rate estimated at 17%–33%, which represents an improvement in recent years, particularly in patients with severe pulmonary hypertension and Eisenmenger syndrome [13]. Mortality is mostly the result of the inability of the right ventricle to accommodate the increased pulmonary artery pressure, leading to right heart failure [2]. The risk of right heart failure is particularly high during the intrapartum and postpartum periods due to the changes in intravascular volume and pressure during these stages [14]. A retrospective review of 49 pregnant women with pulmonary hypertension reported a mortality of 16% [2]. Nearly all of these fatalities occurred in the postpartum period, with the primary cause of death being heart failure, followed by sudden death and thromboembolism. In addition, fetal risks include mortality (11%–28%), premature birth, and growth restriction [14] (Table 15.3). Because of the excess maternal morbidity and mortality risks, pregnancy is contraindicated in patients with PAH. Women who choose to continue pregnancy despite these risks should be followed closely throughout the pregnancy by a multidisciplinary team with expertise in this area [9]. Better outcomes are anticipated in patients who maintain a long-term favorable response to calcium channel blockers (CCBs) [15]. Poor outcomes have been reported in patients with decreased lung diffusion capacity at <45% of normal [3].






















Table 15.3


Maternal and Fetal Complications in Pulmonary Hypertension


Maternal Complications


Fetal Complications


Right heart failure


Preterm birth


Bronchial artery rupture—hemoptysis


Growth restriction


Pulmonary artery dilation leading to


Dissection/rupture


Left recurrent laryngeal nerve compression (hoarseness)


Compression of left main coronary artery (ischemia)


Compression of large airways (wheezing)


Fetal demise


Maternal mortality

Only gold members can continue reading. Log In or Register to continue

Jul 17, 2021 | Posted by in OBSTETRICS | Comments Off on Pulmonary Hypertension in Pregnancy
Premium Wordpress Themes by UFO Themes